Business Information
The group's principal activity is to focus on applying molecular cardiology to the discovery, development and markets of novel, small molecule drugs for the treatment of cardiovascular diseases. The group currently has four compounds in clinical trials. Ranolazine, the first in a new class of compounds known as partial fatty acid oxidation inhibitors. Cvt-510 (tecadenoson), an a1 adenosine receptor agonist, is being developed for the potential reduction of rapid heart rate during atrial arrhythmias. Cvt-3146, an a2a adenosine receptor agonist, is being developed for the potential use as a pharmacologic agent in cardiac perfusion imaging studies. Adentri (TM), an a1 adenosine receptor antagonist, is being developed by the group's partner biogen, inc., for the potential treatment of acute and chronic congestive heart failure.
|
|
Name |
Title
|
Email
|
| Louis Lange | Chmn., CEO, Chief Science Officer | N/A | | Daniel Spiegelman | CFO, Sr. VP | N/A | | Anders Waas | VP - Business Development | N/A | | Brent Blackburn | Sr. VP - Drug Discovery, Development | N/A | | Carol Karp | VP - Regulatory Affairs | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 36,785 | (274,320) | | 2005 | 18,951 | (227,995) | | 2004 | 20,428 | (155,083)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
